Can omega-3 fatty acids be beneficial in pediatric NAFLD? A systematic review and meta-analysis

References

• Africa, J. A., K. P. Newton, and J. B. Schwimmer. 2016. Lifestyle interventions including nutrition, exercise, and supplements for nonalcoholic fatty liver disease in children. Digestive Diseases and Sciences 61 (5):1375–86. doi: 10.1007/s10620-016-4126-1.
   PubMed Web of Science ®Google Scholar
• Akcam, M., A. Boyaci, O. Pirgon, S. Kaya, S. Uysal, and B. N. Dundar. 2011. Therapeutic effect of metformin and vitamin E versus prescriptive diet in obese adolescents with fatty liver. International Journal for Vitamin and Nutrition Research. Internationale Zeitschrift fur Vitamin- und Ernahrungsforschung. Journal International de Vitaminologie et de Nutrition 81 (6):398–406. doi: 10.1024/0300-9831/a000086.
   PubMed Web of Science ®Google Scholar
• Alkhouri, N., R. Kohli, and A. E. Feldstein. 2019. Designing clinical trials in pediatric nonalcoholic steatohepatitis: Tips for patient selection and appropriate endpoints. Hepatology Communications 3 (12):1563–70. doi: 10.1002/hep4.1449.
   PubMed Web of Science ®Google Scholar
• Anderson, E. L., L. D. Howe, H. E. Jones, J. P. T. Higgins, D. A. Lawlor, and A. Fraser. 2015. The prevalence of non-alcoholic fatty liver disease in children and adolescents: A systematic review and meta-analysis. PLoS One 10 (10):e0140908. doi: 10.1371/journal.pone.0140908.
   PubMed Web of Science ®Google Scholar
• Arsik, I., J. Frediani, D. Frezza, W. Chen, T. Ayer, P. Keskinocak, R. Jin, J. Konomi, S. Barlow, S. Xanthakos, et al. 2018. Alanine aminotransferase as a monitoring biomarker in children with nonalcoholic fatty liver disease: A secondary analysis using TONIC trial data. Children (Basel, Switzerland) 5 (6):64. doi: 10.3390/children5060064.
   PubMed Web of Science ®Google Scholar
• Boyraz, M., Ö. Pirgon, B. Dündar, F. Çekmez, and N. Hatipoğlu. 2015. Long-term treatment with n-3 polyunsaturated fatty acids as a monotherapy in children with nonalcoholic fatty liver disease. Journal of Clinical Research in Pediatric Endocrinology 7 (2):121–7. doi: 10.4274/jcrpe.1749.
   PubMed Web of Science ®Google Scholar
• Braun, H. A., S. A. Faasse, and M. B. Vos. 2018. Advances in pediatric fatty liver disease: Pathogenesis, diagnosis, and treatment. Gastroenterology Clinics of North America 47 (4):949–68. doi: 10.1016/j.gtc.2018.07.016.
   PubMed Web of Science ®Google Scholar
• Brunt, E. M., D. E. Kleiner, L. A. Wilson, P. Belt, and B. A. Neuschwander-Tetri. 2011. Nonalcoholic fatty liver disease (NAFLD) activity score and the histopathologic diagnosis in NAFLD: Distinct clinicopathologic meanings. Hepatology (Baltimore, Md.) 53 (3):810–20. doi: 10.1002/hep.24127.
   PubMed Web of Science ®Google Scholar
• Bugianesi, E., S. Moscatiello, M. F. Ciaravella, and G. Marchesini. 2010. Insulin resistance in nonalcoholic fatty liver disease. Current Pharmaceutical Design 16 (17):1941–51. doi: 10.2174/138161210791208875.
   PubMed Web of Science ®Google Scholar
• Chalasani, N., Z. Younossi, J. E. Lavine, A. M. Diehl, E. M. Brunt, K. Cusi, M. Charlton, and A. J. Sanyal. 2012. The diagnosis and management of non-alcoholic fatty liver disease: Practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association. Hepatology (Baltimore, Md.) 55 (6):2005–23. doi: 10.1002/hep.25762.
   PubMed Web of Science ®Google Scholar
• Chen, L. H., Y. F. Wang, Q. H. Xu, and S. S. Chen. 2018. Omega-3 fatty acids as a treatment for non-alcoholic fatty liver disease in children: A systematic review and meta-analysis of randomized controlled trials. Clinical Nutrition (Edinburgh, Scotland) 37 (2):516–21. doi: 10.1016/j.clnu.2016.12.009.
   PubMed Web of Science ®Google Scholar
• Della Corte, C., G. Carpino, R. De Vito, C. De Stefanis, A. Alisi, S. Cianfarani, D. Overi, A. Mosca, L. Stronati, S. Cucchiara, et al. 2016. Docosahexanoic acid plus vitamin D treatment improves features of NAFLD in children with serum vitamin D deficiency: Results from a single centre trial. PLoS One 11 (12):e0168216. doi: 10.1371/journal.pone.0168216.
   PubMed Web of Science ®Google Scholar
• DeVore, S., R. Kohli, K. Lake, L. Nicholas, K. Dietrich, W. F. Balistreri, and S. A. Xanthakos. 2013. A multidisciplinary clinical program is effective in stabilizing BMI and reducing transaminase levels in pediatric patients with NAFLD. Journal of Pediatric Gastroenterology & Nutrition 57 (1):119–23. doi: 10.1097/MPG.0b013e318290d138.
   PubMed Web of Science ®Google Scholar
• Ekstedt, M., L. E. Franzén, U. L. Mathiesen, L. Thorelius, M. Holmqvist, G. Bodemar, and S. Kechagias. 2006. Long-term follow-up of patients with NAFLD and elevated liver enzymes. Hepatology (Baltimore, Md.) 44 (4):865–73. doi: 10.1002/hep.21327.
   PubMed Web of Science ®Google Scholar
• Famouri, F., Z. Shariat, M. Hashemipour, M. Keikha, and R. Kelishadi. 2017. Effects of probiotics on nonalcoholic fatty liver disease in obese children and adolescents. Journal of Pediatric Gastroenterology and Nutrition 64 (3):413–7. doi: 10.1097/MPG.0000000000001422.
   PubMed Web of Science ®Google Scholar
• Feldstein, A. E., P. Charatcharoenwitthaya, S. Treeprasertsuk, J. T. Benson, F. B. Enders, and P. Angulo. 2009. The natural history of non-alcoholic fatty liver disease in children: A follow-up study for up to 20 years. Gut 58 (11):1538–44. doi: 10.1136/gut.2008.171280.
   PubMed Web of Science ®Google Scholar
• Fetterman, J. W., Jr., and M. M. Zdanowicz. 2009. Therapeutic potential of n-3 polyunsaturated fatty acids in disease. American Journal of Health-System Pharmacy 66 (13):1169–79. doi: 10.2146/ajhp080411.
   PubMed Web of Science ®Google Scholar
• Govender, P., M. M. Jonas, A. I. Alomari, H. M. Padua, B. J. Dillon, M. F. Landrigan-Ossar, and G. Chaudry. 2013. Sonography-guided percutaneous liver biopsies in children. AJR. American Journal of Roentgenology 201 (3):645–50. doi: 10.2214/AJR.12.9802.
   PubMed Web of Science ®Google Scholar
• Goyal, P., B. R. Thapa, N. R. Sharma, and A. Bhatia. 2019. Probiotic and lifestyle modification in obese pediatrics with non-alcoholic fatty liver disease. Indian Journal of Community Health 31:50–6.
   Web of Science ®Google Scholar
• Higgins, J. P. T., J. Savović, M. J. Page, R. G. Elbers, and J. A. C. Sterne. 2019. Assessing risk of bias in a randomized trial. Cochrane Handbook for Systematic Reviews of Interventions, 2019, 205–28.
   Google Scholar
• Higgins, J. P. T., J. Thomas, J. Chandler, M. Cumpston, T. Li, M. J. Page, and V. A. Welch. 2020. Cochrane Handbook for Systematic Reviews of Interventions version 6.1 (updated September 2020). www.training.cochrane.org/handbook.
   Google Scholar
• Hudson, O. D., M. Nunez, and G. Q. Shaibi. 2012. Ethnicity and elevated liver transaminases among newly diagnosed children with type 2 diabetes. BMC Pediatrics 12 (1):174. doi: 10.1186/1471-2431-12-174.
   PubMedGoogle Scholar
• Janczyk, W., D. Lebensztejn, A. Wierzbicka-Rucińska, A. Mazur, J. Neuhoff-Murawska, P. Matusik, and P. Socha. 2015. Omega-3 Fatty acids therapy in children with nonalcoholic Fatty liver disease: A randomized controlled trial. The Journal of Pediatrics 166 (6):1358–63.e1-3. doi: 10.1016/j.jpeds.2015.01.056.
   PubMed Web of Science ®Google Scholar
• Khan, R. S., F. Bril, K. Cusi, and P. N. Newsome. 2019. Modulation of insulin resistance in nonalcoholic fatty liver disease. Hepatology (Baltimore, Md.) 70 (2):711–24. doi: 10.1002/hep.30429.
   PubMed Web of Science ®Google Scholar
• Kořínková, L., V. Pražienková, L. Černá, A. Karnošová, B. Železná, J. Kuneš, and L. Maletínská. 2020. Pathophysiology of NAFLD and NASH in experimental models: The role of food intake regulating peptides. Frontiers in Endocrinology 11:597583. doi: 10.3389/fendo.2020.597583.
   PubMed Web of Science ®Google Scholar
• Lavine, J. E., J. B. Schwimmer, J. P. Molleston, A. O. Scheimann, K. F. Murray, S. H. Abrams, P. Rosenthal, A. J. Sanyal, P. R. Robuck, E. M. Brunt, et al. 2010. Treatment of nonalcoholic fatty liver disease in children: TONIC trial design. Contemporary Clinical Trials 31 (1):62–70. doi: 10.1016/j.cct.2009.09.001.
   PubMed Web of Science ®Google Scholar
• Lee, C.-H., Y. Fu, S.-J. Yang, and C.-C. Chi. 2020. Effects of omega-3 polyunsaturated fatty acid supplementation on non-alcoholic fatty liver: A systematic review and meta-analysis. Nutrients 12 (9):2769. doi: 10.3390/nu12092769.
   PubMed Web of Science ®Google Scholar
• Lindenmeyer, C. C., and A. J. McCullough. 2018. The natural history of nonalcoholic fatty liver disease—An evolving view. Clinics in Liver Disease 22 (1):11–21. doi: 10.1016/j.cld.2017.08.003.
   PubMed Web of Science ®Google Scholar
• Ma, X., S. Liu, J. Zhang, M. Dong, Y. Wang, M. Wang, and Y. Xin. 2020. Proportion of NAFLD patients with normal ALT value in overall NAFLD patients: A systematic review and meta-analysis. BMC Gastroenterology 20 (1):10. doi: 10.1186/s12876-020-1165-z.
   PubMed Web of Science ®Google Scholar
• Moher, D., A. Liberati, J. Tetzlaff, and D. G. Altman. 2009. Preferred reporting items for systematic reviews and meta-analyses: The PRISMA statement. PLoS Medicine 6 (7):e1000097. doi: 10.1371/journal.pmed.1000097.
   PubMed Web of Science ®Google Scholar
• Moslehi, A., and Z. Hamidi-Zad. 2018. Role of SREBPs in liver diseases: A mini-review. Journal of Clinical and Translational Hepatology 6 (3):332–8. doi: 10.14218/JCTH.2017.00061.
   PubMed Web of Science ®Google Scholar
• Musa-Veloso, K., C. Venditti, H. Y. Lee, M. Darch, S. Floyd, S. West, and R. Simon. 2018. Systematic review and meta-analysis of controlled intervention studies on the effectiveness of long-chain omega-3 fatty acids in patients with nonalcoholic fatty liver disease. Nutrition Reviews 76 (8):581–602. doi: 10.1093/nutrit/nuy022.
   PubMed Web of Science ®Google Scholar
• Musso, G., M. Cassader, E. Paschetta, and R. Gambino. 2018. Bioactive lipid species and metabolic pathways in progression and resolution of nonalcoholic steatohepatitis. Gastroenterology 155 (2):282–e8-302.e8. doi: 10.1053/j.gastro.2018.06.031.
   PubMed Web of Science ®Google Scholar
• Nobili, V., A. Alisi, C. Della Corte, P. Risé, C. Galli, C. Agostoni, and G. Bedogni. 2013. Docosahexaenoic acid for the treatment of fatty liver: Randomised controlled trial in children. Nutrition, Metabolism, and Cardiovascular Diseases: NMCD 23 (11):1066–70. doi: 10.1016/j.numecd.2012.10.010.
   PubMed Web of Science ®Google Scholar
• Nobili, V., A. Alisi, L. Valenti, L. Miele, A. E. Feldstein, and N. Alkhouri. 2019. NAFLD in children: New genes, new diagnostic modalities and new drugs. Nature Reviews. Gastroenterology & Hepatology 16 (9):517–30. doi: 10.1038/s41575-019-0169-z.
   PubMed Web of Science ®Google Scholar
• Nobili, V., G. Bedogni, A. Alisi, A. Pietrobattista, P. Rise, C. Galli, and C. Agostoni. 2011. Docosahexaenoic acid supplementation decreases liver fat content in children with non-alcoholic fatty liver disease: Double-blind randomised controlled clinical trial. Archives of Disease in Childhood 96 (4):350–3. doi: 10.1136/adc.2010.192401.
   PubMed Web of Science ®Google Scholar
• Nobili, V., M. Manco, R. Devito, V. Di Ciommo, D. Comparcola, M. R. Sartorelli, F. Piemonte, M. Marcellini, and P. Angulo. 2008. Lifestyle intervention and antioxidant therapy in children with nonalcoholic fatty liver disease: A randomized, controlled trial. Hepatology (Baltimore, Md.) 48 (1):119–28. doi: 10.1002/hep.22336.
   PubMed Web of Science ®Google Scholar
• Ouzzani, M., H. Hammady, Z. Fedorowicz, and A. Elmagarmid. 2016. Rayyan—A web and mobile app for systematic reviews. Systematic Reviews 5 (1):210. doi: 10.1186/s13643-016-0384-4.
   PubMedGoogle Scholar
• Pacifico, L., E. Bonci, M. Di Martino, P. Versacci, G. Andreoli, L. M. Silvestri, and C. Chiesa. 2015. A double-blind, placebo-controlled randomized trial to evaluate the efficacy of docosahexaenoic acid supplementation on hepatic fat and associated cardiovascular risk factors in overweight children with nonalcoholic fatty liver disease. Nutrition, Metabolism, and Cardiovascular Diseases: NMCD 25 (8):734–41. doi: 10.1016/j.numecd.2015.04.003.
   PubMed Web of Science ®Google Scholar
• Rong, Y., N. Chun-Yan, Z. Hong-Xin, Y. Lu, W. Wen, and T. Yu. 2018. Association of adolescent obesity with nonalcoholic fatty liver disease and related risk factors in Xi’an, China. Annals of Hepatology 17 (1):85–91. doi: 10.5604/01.3001.0010.7538.
   PubMed Web of Science ®Google Scholar
• Saadeh, S., Z. M. Younossi, E. M. Remer, T. Gramlich, J. P. Ong, M. Hurley, K. D. Mullen, J. N. Cooper, and M. J. Sheridan. 2002. The utility of radiological imaging in nonalcoholic fatty liver disease. Gastroenterology 123 (3):745–50. doi: 10.1053/gast.2002.35354.
   PubMed Web of Science ®Google Scholar
• Sarkhy, A. A., A. A. Al-Hussaini, and V. Nobili. 2014. Does vitamin E improve the outcomes of pediatric nonalcoholic fatty liver disease? A systematic review and meta-analysis. Saudi Journal of Gastroenterology 20 (3):143–53. doi: 10.4103/1319-3767.132983.
   PubMed Web of Science ®Google Scholar
• Schwimmer, J. B., K. P. Newton, H. I. Awai, L. J. Choi, M. A. Garcia, L. L. Ellis, K. Vanderwall, and J. Fontanesi. 2013. Paediatric gastroenterology evaluation of overweight and obese children referred from primary care for suspected non-alcoholic fatty liver disease. Alimentary Pharmacology & Therapeutics 38 (10):1267–77. doi: 10.1111/apt.12518.
   PubMed Web of Science ®Google Scholar
• Scorletti, E., and C. D. Byrne. 2018. Omega-3 fatty acids and non-alcoholic fatty liver disease: Evidence of efficacy and mechanism of action. Molecular Aspects of Medicine 64:135–46. doi: 10.1016/j.mam.2018.03.001.
   PubMed Web of Science ®Google Scholar
• Tannapfel, A., H. Denk, H.-P. Dienes, C. Langner, P. Schirmacher, M. Trauner, and B. Flott-Rahmel. 2011. Histopathological diagnosis of non-alcoholic and alcoholic fatty liver disease. Virchows Archiv: An International Journal of Pathology 458 (5):511–23. doi: 10.1007/s00428-011-1066-1.
   PubMed Web of Science ®Google Scholar
• Vajro, P., S. Lenta, P. Socha, A. Dhawan, P. McKiernan, U. Baumann, O. Durmaz, F. Lacaille, V. McLin, V. Nobili, et al. 2012. Diagnosis of nonalcoholic fatty liver disease in children and adolescents: Position paper of the ESPGHAN Hepatology Committee. Journal of Pediatric Gastroenterology and Nutrition 54 (5):700–13. doi: 10.1097/MPG.0b013e318252a13f.
   PubMed Web of Science ®Google Scholar
• Vos, M. B., S. H. Abrams, S. E. Barlow, S. Caprio, S. R. Daniels, R. Kohli, M. Mouzaki, P. Sathya, J. B. Schwimmer, S. S. Sundaram, et al. 2017. NASPGHAN clinical practice guideline for the diagnosis and treatment of nonalcoholic fatty liver disease in children: Recommendations from the Expert Committee on NAFLD (ECON) and the North American Society of Pediatric Gastroenterology, Hepatology and Nutrition (NASPGHAN). Journal of Pediatric Gastroenterology and Nutrition 64 (2):319–34. doi: 10.1097/MPG.0000000000001482.
   PubMed Web of Science ®Google Scholar
• Vuppalanchi, R., A. K. Jain, R. Deppe, K. Yates, M. Comerford, H. C. Masuoka, B. A. Neuschwander-Tetri, R. Loomba, E. M. Brunt, D. E. Kleiner, et al. 2014. Relationship between changes in serum levels of keratin 18 and changes in liver histology in children and adults with nonalcoholic fatty liver disease. Clinical Gastroenterology and Hepatology 12 (12):2121–2. doi: 10.1016/j.cgh.2014.05.010.
   PubMed Web of Science ®Google Scholar
• Yu, E. L., S. Golshan, K. E. Harlow, J. E. Angeles, J. Durelle, N. P. Goyal, K. P. Newton, M. C. Sawh, J. Hooker, E. Z. Sy, et al. 2019. Prevalence of nonalcoholic fatty liver disease in children with obesity. The Journal of Pediatrics 207:64–70. doi: 10.1016/j.jpeds.2018.11.021.
   PubMed Web of Science ®Google Scholar
• Zöhrer, E., A. Alisi, J. Jahnel, A. Mosca, C. Della Corte, A. Crudele, G. Fauler, and V. Nobili. 2017. Efficacy of docosahexaenoic acid-choline-vitamin E in paediatric NASH: A randomized controlled clinical trial. Applied Physiology, Nutrition, and Metabolism = Physiologie Appliquee, Nutrition et Metabolisme 42 (9):948–54. doi: 10.1139/apnm-2016-0689.
   PubMed Web of Science ®Google Scholar